I. PURPOSE

To specify the procedures for executing reliance agreements between the UTHSC and collaborating institutions.

II. SCOPE

This SOP applies to all investigators and key study personnel performing research under the auspices of the University of Tennessee Health Science Center IRB and its affiliated institutions.

Personnel responsible:

IRB administrative staff, IRB members, and investigators.

III. BACKGROUND

An IRB authorization agreement (or reliance agreement or cooperative agreement) is a contract between two or more organizations that delineates and documents the respective responsibilities, roles and processes of communication between an organization that provides ethical and regulatory review of human subjects research (via the reviewing IRB) and collaborating organizations that accept the determinations of the reviewing IRB (via the relying IRB(s)). Reliance agreements may cover a single study, a series of similar studies, all studies conducted by a consortium of research institutions, or all studies conducted by a relying institution. The institution providing the reviewing IRB need not be a study site (e.g., it might be a central IRB designated by a consortium of research institutions or a commercial IRB utilized by the sponsor of a multicenter study).

Under a reliance agreement, the reviewing IRB is responsible for primary IRB functions, including, but not limited to, approval of the initial study application, continuations and study revisions for all study sites subject to the agreement. The reviewing IRB or local site investigators must communicate the results of its actions and the associated documentation to the relying IRBs. The reviewing IRB must also make its policies available to the relying IRBs and provide contacts for local investigators and relying IRBs to obtain answers to questions, to express concerns, or to convey suggestions regarding its reviews. Other oversight functions are typically assigned to the relying IRBs. These latter functions include assuring the qualifications
of local investigators and their training regarding regulatory requirements, managing researcher and research staff conflicts of interest, submitting required local information for consent forms, and reporting to the reviewing IRB any unanticipated problems, protocol deviations, non-compliance by local investigators, and results of audits occurring at the local site(s). Processes for some additional oversight functions are subject to negotiation between the reviewing IRB and relying IRB in reliance agreements. These functions include clarifying local context information (e.g., special characteristics of the local subject population), reporting serious or continuing non-compliance to regulatory authorities, and completion of other required regulatory reviews related to biosafety, radiation safety, and HIPAA privacy protections, as applicable. Given the complexity of some reliance agreements, the terms of these arrangements must be reviewed in consultation with the local site investigator and fully vetted by the UTHSC IRB before the University will enter into a reliance agreement. The initial reliance agreement must then be reviewed and approved by the UTHSC IRB on behalf of the University. Furthermore, if another institution is requesting the addition of indemnification language to a reliance agreement, UTHSC Sponsored Programs and/or the equivalent office at our affiliate institution(s) must review and approve this language before the University will execute the reliance agreement. At this time, the UTHSC IRB executes reliance agreements for non-exempt human subjects research only. Exempt research for which limited IRB review takes place pursuant to §46.104(d)(2)(iii), (d)(3)(i)(C), or (d)(7) or (8) must be reviewed locally, as with other human subjects research that is exempt from HHS regulations but does not require limited IRB review.

Due to the mutual responsibilities of reviewing and relying IRBs under reliance agreements, local site investigators must maintain comprehensive communication with both the reviewing IRB and the UTHSC IRB when UTHSC is the relying IRB. Local investigators must register the study with the UTHSC IRB prior to execution of the reliance agreement and later provide all communications and documents regarding actions of the reviewing IRB related to approval of the initial study application, continuations, and revisions throughout the life of the study. Changes to local key study personnel as well as information regarding unanticipated problems, protocol deviations, incidents of non-compliance, and study closure must also be communicated to the UTHSC IRB. These communications enable the UTHSC IRB to fulfill its monitoring responsibilities under the reliance agreement and to report its own findings to the reviewing IRB.

Recent revisions of NIH policies and Federal regulations for the protection of human subjects will significantly increase the use of reliance agreements for regulatory oversight of multicenter human research studies. The NIH Single IRB Policy for Multi-site Research is effective for applications with due dates on or after January 25, 2018 and contract solicitations published on or after January 25, 2018. With the exception of career development, research training and fellowship awards, this policy applies to the domestic sites of NIH-funded multi-site studies, where each site will implement the same protocol involving non-exempt human subjects research, whether supported through grants, cooperative agreements, contracts, or the NIH
intramural program. For such studies, a single IRB must be designated to fulfill primary IRB functions related to approval of initial applications, continuations, and study revisions. Local sites must execute reliance agreements with the organization hosting the designated reviewing IRB in order to participate in these NIH-funded studies. Similarly, under a provision of the revised Common Rule that took effect on January 20, 2020, any institution located in the United States that is engaged in cooperative human subjects research involving multiple sites and covered by the Common Rule must rely upon approval of a single IRB for that portion of the research that is conducted in the United States. Participating sites must establish reliance agreements with the organization hosting the reviewing IRB.

In accordance with:

**DHHS:** 45 CFR 46.103(b)(2), 45 CFR 46.103(d), 45 CFR 46.109(d), 45 CFR 46.114

**FDA:** 21 CFR 56.109(e), 21 CFR 56.114, FDA Information Sheet: Non-Local IRB Review, and Information Sheet: Cooperative Research

**NIH:** Policy on the Use of a Single Institutional Review Board for Multi-Site Research (June 21, 2016)

*Compliance with this policy also requires compliance with state or local laws and regulations that provide additional protections for human subjects.*

**IV. DEFINITIONS**

1. **Federalwide Assurance (FWA)** is a contractual agreement between an institution engaged in human subjects research and the Office for Human Research Protections (OHRP) of the Department of Health and Human Services (HHS) in which the institution agrees to comply with federal regulations for the protection of human subjects at 45 CFR 46 in research that is conducted or supported by HHS. An institution’s commitment under an FWA also applies to research conducted or supported by other federal departments and agencies that have adopted the basic federal policy for the protection of human subjects (45 CFR 46, subpart A, also known as the Common Rule) and, in that sense, it is “federalwide.”

2. **IRB Authorization Agreement** (also called a **Reliance Agreement**) is a contract which documents the respective responsibilities, roles and processes of communications between an organization whose IRB provides regulatory review (i.e., the reviewing institution) and another organization that relies upon the reviewing IRB to complete primary IRB functions (i.e., the relying institution). These functions include (but are not limited to) approval of new applications, continuing reviews, and study revisions performed on behalf of the relying institution. Authorization agreements may cover a single study or multiple studies conducted by the relying institution.
3. **Non-Regulatory IRB Review** is a full board UTHSC IRB review of a study for which it is proposed that the UTHSC IRB serve as a relying IRB under a reliance agreement. This non-regulatory IRB review is conducted at the request of any affiliate institution for which the UTHSC IRB serves as the IRB of record under the latter’s FWA. Such a review would not count for regulatory purposes where review by a single IRB is required either by federal regulations or the funding source. Rather, the review would enable the affiliate institution to receive consultative advice regarding whether the proposed study meets general criteria and local standards for IRB approval, and whether it should be supported at the local site(s). If the study is determined to be acceptable, then official regulatory review would be provided by the IRB designated as the reviewing IRB under the reliance agreement.

4. **Overall Principal Investigator** is the individual who serves as the lead investigator for a multicenter study. The overall principal investigator will frequently be a faculty or staff member of the institution whose IRB serves as the reviewing IRB for a multicenter study. However, for arrangements like a research consortium, the designated reviewing IRB for the consortium research activities may be attached to a different institution from the institution of the overall principal investigator for a particular study.

5. **Reviewing IRB** (also called the **IRB of record**) is the IRB designated under an authorization or reliance agreement to fulfill primary IRB regulatory functions on behalf of the relying institution(s) including, but not limited to, approval of new applications, continuing reviews, and approval of study revisions. The reviewing IRB designated under a reliance agreement may be one of several types. A **central IRB** provides regulatory review for all sites participating in a consortium of institutions undertaking more than one multicenter study. The NCI CIRB is an example of a central IRB for cooperative group oncology studies. A **single IRB** is the IRB which provides regulatory review for all sites in a single, multicenter study. A single IRB will often be the IRB of the lead site for the multicenter study. An **independent IRB** is the reviewing IRB for a single multicenter study but is not associated with any of the study sites. Commercial IRBs often serve in this capacity.

6. **IRB Reliance Manager** is the UTHSC staff member with primary responsibilities of reviewing applications from investigators to establish reliance agreements and for ensuring implementation of reliance agreements according to the terms specified therein.

7. **Relying IRB** is the IRB of an institution engaged in human subjects research that enters into an IRB authorization agreement (reliance agreement) whereby the institution cedes primary IRB review functions for research in which it is engaged to an IRB associated with another institution. Under most reliance agreements, the relying IRB continues to exercise several important responsibilities related to the regulatory oversight of the research as it is conducted at the local site(s). These include assuring the qualifications of local investigators and their training regarding regulatory requirements, managing researcher and research staff conflicts of interest, submitting required local information for consent forms, and
reporting to the reviewing IRB any unanticipated problems, protocol deviations, non-compliance by local investigators, and audit results at the local site(s).

8. **Relying Site/Institution** is an institution engaged in human subjects research that enters into an IRB authorization agreement (reliance agreement) whereby it cedes IRB review of human subjects research in which it is engaged to an IRB associated with another institution.

9. **Site Principal Investigator** is an individual who has primary responsibility for the conduct of a multicenter human subjects research study at a particular site or institution. Unless the site principal investigator is also the overall principal investigator for a multicenter study, the site principal investigator will be associated with an institution that has ceded IRB review of the study to the IRB of another institution.

10. **SMART IRB** is a consortium of institutions that utilizes a standardized IRB reliance agreement specifying the roles and responsibilities of all institutions involved in the regulatory review and conduct of multi-site research. The SMART IRB initiative was developed with NIH funding to facilitate the implementation of its single IRB policy. The agreement specifies the responsibilities of the participating institutions, the reviewing IRB, and the relying IRBs, as well as outlines the communication process between the reviewing IRB and the relying institutions. The SMART IRB reliance agreement is endorsed by NIH for use in its multicenter studies. UTHSC and its affiliate institutions (i.e., Le Bonheur Children’s Hospital, Methodist Healthcare - Memphis Hospitals/UT Methodist Physicians, and Regional One Health) are members of this consortium and do participate in multicenter research studies under the SMART IRB reliance agreement. However, the SMART IRB consortium does not have its own IRB and does not provide IRB review.

V. **PROCEDURES**

1. **UTHSC as the Reviewing IRB**
   a. The **overall principal investigator** must first contact the **IRB Reliance Manager** in order to determine whether the study meets the criteria for the use of an IRB Authorization Agreement (IAA) and whether the UTHSC IRB has the capability to serve as the reviewing IRB. The UTHSC IRB will also review the qualifications/expertise of the members of the UTHSC IRB and the staff resources of the UTHSC IRB to serve as the reviewing IRB for the study, the qualifications of the overall principal investigator to lead the study, as well as the adequacy of the research support staff to oversee the conduct of the multicenter study. The IRB Reliance Manager, in consultation with the IRB Director or their designee, will determine whether these criteria, as well as those below pertaining to the evaluation of proposed study sites, are satisfied.
   b. Once the UTHSC IRB has initially agreed to serve as the reviewing IRB under a reliance agreement, the overall principal investigator must submit the study to the UTHSC IRB via iMedRIS for approval before it is initiated at any site. The submission must include all required components as follows:
i. Application, master protocol, consent form(s), investigator’s brochure(s), recruitment materials, data collection tools, etc.;

ii. A list of **proposed relying research sites** must be included within the application, with confirmation that the external site investigator(s) have contacted their respective institution(s) to obtain any requisite local reviews and/or initiate the reliance process with their respective IRB(s);

iii. Information regarding **local requirements** and **local research context issues** at the external site(s), which must be requested from the relying site IRB(s); and

iv. An unsigned copy of the reliance agreement completed in accord with the [IRB Agreement – Instructions for Use](#) (NOTE: A copy of the reliance agreement does not need to be attached to the submission if it is an existing IRB authorization agreement that has been fully executed and is already on file with the UTHSC IRB, such as the overarching agreements maintained with St. Jude Children’s Research Hospital, the University of Memphis, the National Cancer Institute (NCI) Central IRB (CIRB), the National Marrow Donor Program (NMDP), etc.).

c. The UTHSC IRB will evaluate the proposed relying site(s) submitted via the above-referenced iMedRIS application that will address the following items:

i. Determination of whether each relying site has a **Federalwide Assurance** and (if applicable) whether each organization uses different but equivalent protections for research not covered by HHS regulations, or whether the same policies and procedures are applied to all research conducted at the site;

ii. Determination of whether each organization is **AAHRPP-accredited** or a **SMART IRB participating institution**;

iii. Evaluation of the qualifications of the site investigators and research staff, including their research workload;

iv. Adequacy of the resources at the proposed relying site(s), including space, equipment, and personnel;

v. Review of national, state, or local laws or regulations directly relevant to the conduct of the study at the proposed site(s);

vi. When relevant, information about the local study population, including information about culture, race/ethnicity, socioeconomic status(es), language(s) spoken, religious affiliation(s), health literacy or general literacy level(s), and whether the local research population involves discrete and insular communities;

vii. Information about the recruitment and informed consent processes at the local site(s), including local recruitment materials, research staff who will obtain informed consent, the location and process of the consent discussion, and primary language(s) spoken by participants and persons obtaining consent;

viii. Information regarding whether research procedures at the local site(s) will differ from the master protocol submitted and whether sufficient resources are available at the local research site(s) to carry out the research as stated;

ix. Determination of whether the relying organization requires any site-specific language in the approved consent document(s), such as local contacts for research participants’ questions or a compensation for injury disclaimer;
x. Plans to protect the confidentiality of subjects’ information, including methods of storing and transmitting paper and electronic records;

xi. If not managed centrally by a pharmacy at the organization, study-specific information about plans for the storage, handling, and dispensing of drugs and medical devices at the site(s);

xii. Determination of whether site researchers or research staff have financial or other conflicts of interest related to the research and, if so, the management plan proposed by the organization of the relying site;

xiii. Confirmation that site researchers and research staff have completed required educational training regarding ethical and regulatory requirements for the conduct of human subjects research;

xiv. If required ancillary reviews (e.g., biosafety or radiation safety reviews) must be completed at the local site, documentation regarding the outcome of those reviews; and

xv. Contact information for the organizational official or designee who will manage the reliance agreement at the relying site(s).

d. Reliance agreements will not take effect until signed on behalf of UTHSC by the Vice Chancellor for Research as the UTHSC institutional official’s signatory designee and fully executed by the relying institution(s).

e. As the reviewing IRB, the UTHSC IRB assumes sole responsibility for conducting review of multi-center research to determine whether it is ethically justifiable according to all applicable regulations and laws, as well as UTHSC IRB and, if applicable, affiliate institutional policies, including the initial review of applications, continuing review, and revisions to previously approved research.

f. The UTHSC IRB does not permit initiation of a study covered under the reliance agreement or the enrollment of study participants at any site until its conduct has been approved at the site by the UTHSC IRB, the relying organization has officially confirmed its acceptance of the reliance agreement, and all other applicable requirements and approvals for the study have been secured for that site (such as biosafety and radiation safety reviews as well as requisite institutional approvals).

g. For studies subject to HHS regulations for the protection of human subjects, the UTHSC IRB will secure, prior to initiation of research with the corresponding vulnerable subject population at any site, any required additional approvals from HHS when studies involve pregnant women, fetuses and neonates, children, and/or prisoners, unless an alternative process has been delineated in the reliance agreement.

h. When serving as the reviewing IRB for studies funded by NIH, the UTHSC IRB acknowledges that the requirement for single IRB review applies to all awardees and participating sites in the United States but does not apply to organizations outside the United States. Participating sites may conduct their own IRB review only if it is in accord with the NIH policy on exceptions from single IRB review.

i. The UTHSC IRB requires that researchers at all sites obtain, document, and maintain records of consent by each participant or LAR as specified in the approved study application and supporting documentation. The consent documents for each site must
also include any **locally required consent template language** as specified in the reliance agreement.

j. For the **addition of investigative sites**, the UTHSC IRB conducts the review on an expedited basis as a minor revision to previously approved studies, using the vetting process described above.

k. When researchers or research staff at a non-federal relying institution have a **conflict of interest**, the non-federal relying institution must submit a description of the conflict of interest and proposed management plan to the UTHSC IRB in accord with the policies of the affected site. The UTHSC IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation in the research study and may propose additional requirements for the management plan in consultation with the non-federal relying institution. If the non-federal relying institution is unable to accept the additional elements of the management plan as negotiated, then the UTHSC IRB cannot approve the conduct of the research at the affected site.

l. The UTHSC IRB will ask via the questions in the reliance agreement request whether **organizational conflicts of interest** exist at participating study sites. If so, the relying institution must submit a description of the conflict of interest and proposed management plan to the UTHSC IRB in accord with the policies of the affected site. The UTHSC IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation of the relying site in the research study and may propose additional requirements for the management plan in consultation with the relying institution. If the relying organization is unable to accept the additional elements of the management plan as negotiated, then the UTHSC IRB cannot approve the conduct of the research at the affected site.

m. The UTHSC IRB has final authority for determining whether **reported events** constitute unanticipated problems involving risks to subjects or others. The UTHSC IRB will determine whether these events require revision, suspension, or termination of the study in order to minimize the risk of harm to subjects or others. In addition, the UTHSC IRB will report these events to institutional officials, sponsors, and federal regulatory bodies as specified in its corresponding SOP. Any additional reporting responsibilities or prerogatives of the relying organizations must be addressed in the reliance agreement.

n. The overall principal investigator must promptly provide to the UTHSC IRB all **data and safety monitoring reports** received from the duly constituted oversight group for the study.

o. The UTHSC IRB maintains the authority to undertake or request **audits** of the research at all participating sites, and to receive and act upon the reports of such audits, as specified in the reliance agreement.

p. The UTHSC IRB will require participating sites to submit reports of any event involving **potential non-compliance**, including results of audits, complaints, and protocol deviations. The UTHSC IRB will determine whether the reported event has a basis in fact, and whether it represents an instance of serious and/or continuing non-compliance, unless responsibility for this process is otherwise assigned to the relying organization(s) in the reliance agreement.
q. The UTHSC IRB assumes final authority for determining whether identified instances of serious and/or continuing non-compliance require revision, suspension, or termination of the study at the affected site.

r. For studies subject to HHS and/or FDA regulations for the protection of human subjects, the UTHSC IRB will report instances of serious and/or continuing non-compliance to institutional officials, sponsors, and federal regulatory bodies as specified in its corresponding SOP. Any additional reporting responsibilities of the relying organization(s) will be addressed in the reliance agreement.

s. The UTHSC IRB assumes responsibility for determining the congruency of any federal grant supporting the research study with the activities described in the proposed study, or with the activities being undertaken in a previously approved study where the grant is obtained after initial review and approval has occurred. The UTHSC IRB may require the lead investigator to resolve any discrepancies identified or to provide clarification regarding the reasons for apparent discrepancies.

t. Researchers and research staff at all sites must meet UTHSC IRB requirements for training in the ethics and regulation of human subjects research, unless otherwise specified in the reliance agreement.

u. For NIH-funded studies, the UTHSC IRB will assure that investigators meet the additional requirements of the NIH Genomic Data Sharing Policy, unless the process is otherwise specified in the reliance agreement.

v. The UTHSC IRB will require that the overall principal investigator notify all site principal investigators and, if applicable, the relying organizations of all UTHSC IRB decisions regarding the multi-site study, consistent with the terms of the applicable reliance agreement.

w. The UTHSC IRB will make available relevant IRB records including, but not limited to, minutes, approved applications and protocols, approved consent forms, and other records that document the IRB’s determinations, to the relying organizations upon request and as specified in the applicable reliance agreement.

x. The UTHSC IRB will make relevant SOPs readily available to the relying organizations, including the staff of human research protections programs, and researchers and research staff, and will communicate with relying organizations via iMedRIS when relevant local policies undergo major revisions that may affect any procedures covered under the reliance agreement.

y. The UTHSC IRB will provide the name of its IRB reliance manager and contact information to the relying organizations, researchers, and research staff so that relying sites may obtain answers to questions, express concerns, and/or convey suggestions regarding the actions of the UTHSC IRB.

z. In the event that the reliance agreement is terminated by either party, within 30 business days, the UTHSC will negotiate with the relying organization to determine responsibility for oversight of any study conducted at that site and previously covered by the reliance agreement, until such time as the relevant study is closed.

aa. The UTHSC IRB will be responsible for developing HIPAA authorization language in consent forms, as well as for making determinations regarding waivers or alterations of authorization under the HIPAA Privacy Rule, unless otherwise specified in the reliance
agreement. If the relying institution has required site-specific HIPAA authorization language for the consent forms or a standalone HIPAA authorization form, this language must be communicated to the UTHSC IRB for inclusion in the site-specific consent forms or in a standalone HIPAA authorization form. Similarly, concerns of a relying institution regarding HIPAA waivers or alterations should be communicated to and negotiated with the UTHSC IRB. Although HIPAA determinations will be made by the UTHSC IRB unless otherwise specified in the reliance agreement, relying institutions remain solely responsible for fulfilling their obligations under the HIPAA Privacy Rule.

2. Responsibilities of Overall Principal Investigators with UTHSC as the Reviewing IRB:
   a. The overall principal investigator and research team are responsible for understanding the requirements of the reliance agreement under which the UTHSC IRB is serving as the reviewing IRB for the study.
   b. The overall principal investigator must work in collaboration with the UTHSC IRB and its IRB Reliance Manager to determine and document specific roles and responsibilities for coordinating and communicating key information to relying institutions and the UTHSC IRB as specified in the reliance agreement.
   c. The overall principal investigator must be knowledgeable about and follow all policies and procedures of the UTHSC IRB as the reviewing IRB for the study and assure that site investigators are provided those policies and procedures.
   d. The overall principal investigator is responsible for ensuring that all relying site researchers and research staff disclose conflicts of interest in accord with their institutional policies. The relying institution must convey to the UTHSC IRB any management plan that results from their local COI review process. The UTHSC IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation of the affected personnel in the research study and may propose additional requirements for the management plan in consultation with the relying site. If the UTHSC IRB or the relying site is unable to accept the additional elements of the management plan as negotiated, then the research cannot be conducted at the relying site. Management plans must be finalized and implemented before the study can be initiated or continued (if the conflict arises during conduct of the study) at the relying site.
   e. The overall principal investigator must ensure that relying sites do not initiate the study prior to their institutional approval of the reliance agreement and acceptance of conduct of the research study at the relying site.
   f. The overall principal investigator must also ensure that relying sites do not initiate the study covered under the reliance agreement or enroll study participants until its conduct at the relying site has been reviewed and approved by the UTHSC IRB.
   g. The overall principal investigator must further ensure that initiation of the study or enrollment of study participants at the relying site(s) does not occur until all other applicable requirements and approvals (e.g., Institutional Biosafety Committee, Radiation Safety Committee, etc.) for the study have been secured, as specified in the reliance agreement.
h. The overall principal investigator is responsible for ensuring that information is obtained from all relying sites regarding proposed local variations in study conduct, recruitment materials and process, and the locally required consent language and process and communicating this information to the UTHSC IRB.

i. The overall principal investigator is responsible for ensuring that relying sites comply with the determinations of the UTHSC IRB with regard to initial review, continuing review, and review of revisions for studies covered under the reliance agreement. Communication to and acceptance of those determinations by relying sites must be documented via iMedRIS by the overall principal investigator.

j. The overall principal investigator is responsible for providing relying sites and their IRBs with any information that is requested by the relying sites.

k. The overall principal investigator must ensure that investigators at all relying sites obtain, document, and maintain records of informed consent by each participant or LAR as specified by the UTHSC IRB. The consent document(s) must also include locally required consent template language as specified in the reliance agreement.

l. The overall principal investigator is responsible for ensuring that relying study sites submit required information to the UTHSC IRB prior to continuing review. If such information is not submitted in a timely fashion by any relying site, the overall principal investigator must report the absence of the required information in the continuing review application, inform the affected site that there is a lapse of approval at the affected site, and determine an appropriate corrective action plan in consultation with the affected site and the UTHSC IRB.

m. The overall principal investigator must ensure that any proposed revisions to the research at relying sites are submitted to and approved by the UTHSC IRB prior to implementation, except where necessary to eliminate apparent immediate hazards to the participants.

n. The overall principal investigator is responsible for promptly reporting to the UTHSC IRB any unanticipated problems occurring at any study site being overseen by the UTHSC IRB involving risks to subjects or others according to the requirements specified in the reliance agreement. These unanticipated problems must also be reported to the relying IRB after the UTHSC IRB has made a determination.

o. The overall principal investigator must promptly provide to the UTHSC IRB all data and safety monitoring reports and must provide those reports and any determinations of the UTHSC IRB regarding revisions necessitated by the data and safety monitoring reports to relying site IRBs and investigators.

p. The overall principal investigator must cooperate with the UTHSC IRB and the relying institutions to facilitate the completion of any audits conducted according to procedures specified in the reliance agreement. The UTHSC IRB will share the results of those audits with the affected site principal investigators and institutions.

q. The overall principal investigator must promptly report to the UTHSC IRB and relying site affected any potential instances at the study site of non-compliance, including results of audits, complaints, and protocol deviations. Such events initially identified at the relying sites must also be promptly reported to the UTHSC IRB.
r. The overall principal investigator retains the obligation to provide relying sites and their IRBs with copies of the UTHSC IRB documents on any future actions that it takes with respect to the study covered by the reliance agreement, such as review of revisions, continuations, protocol deviations, etc., and any suspension of subject enrollment or the study itself.

s. The overall principal investigator is responsible for ensuring that researchers and research staff at relying sites satisfy their local requirements for training in the ethics and regulation of human subjects research and provide documentation thereof to the UTHSC IRB as specified in the reliance agreement.

3. UTHSC as the Relying IRB
   a. The site principal investigator must first contact the IRB Reliance Manager in order to determine whether the study meets the criteria for the use of an IAA and whether the UTHSC IRB will agree to serve as a relying IRB for the multicenter study. During this consultation, a short survey will be administered in order to gather basic information about the study activities and whether the research presents more than minimal risk. If the study presents more than minimal risk, the UTHSC IRB will serve as a relying IRB only if the use of a single reviewing IRB is a regulatory requirement and/or otherwise necessary for participation in the study. These circumstances include:
      i. Use of the Central IRB of the National Cancer Institute;
      ii. The funding agency or sponsor of the study requires single IRB review as a condition of funding;
      iii. Federal regulations, state laws, or local policies require the use of a single reviewing IRB; and/or
      iv. UTHSC is a participant in a research consortium that requires the use of a single IRB.
      The initial consultation survey will confirm whether use of an external IRB for research that presents greater than minimal risk is permitted by UTHSC according to the above-listed criteria and may request supporting documentation based on the response provided. A copy of the initial consultation survey will be provided to the site principal investigator for confirmation of accuracy and record-keeping purposes.

b. If the initial consultation survey responses meet the initial criteria above in (V)(3)(a)(i, ii, iii, and/or iv) for use of an external IRB, the proposed reviewing IRB will be vetted based on the following criteria set forth in (V)(3)(b)(i, ii, and/or iii) and, if applicable, (V)(3)(b)(i-vi):

   With regard to the conduct of minimal risk research, the UTHSC IRB will vet the proposed reviewing IRB according to the following considerations:
      i. If the institution of which the reviewing IRB is a component conducts human subjects research, it has a Federalwide Assurance, provides its FWA number, and (if relevant) indicates whether the organization uses different but equivalent protections for research not covered by HHS regulations, or whether the same policies and procedures are applied to all research conducted at the site;
      ii. The reliance agreement and any addenda provide assurance that the reviewing IRB will conduct its review consistent with applicable ethical standards and regulations, and will report during the study to the UTHSC IRB any regulatory violations by or
investigations of the reviewing IRB by regulatory agencies, such as OHRP, FDA, or regulatory agencies in other countries; and/or

iii. If applicable, the UTHSC IRB’s prior experience relying on the proposed reviewing IRB.

c. For greater than minimal risk research, UTHSC will permit the UTHSC IRB to serve as the relying IRB only if the criteria set forth in (V)(3)(b)(i, ii, and/or iii) as well as the following criteria are satisfied:

i. The organization providing the reviewing IRB has an AAHRPP-accredited human research protections program or is a SMART IRB Participating Institution;

ii. The membership of the reviewing IRB is properly constituted to conduct review of the research according to applicable laws and regulations;

iii. Members of the reviewing IRB do not participate in the review of any studies under the reliance agreement with respect to which they have a conflict of interest;

iv. If applicable, the UTHSC IRB determines that initial review of the study has been properly conducted by the reviewing IRB, based on evaluation by the UTHSC IRB of the protocol, study application, consent forms, outcome letters and other pertinent materials submitted from the initial review of the application (e.g., questionnaires, advertisements, reviewer comments and minutes of relevant meetings when available). Further, the UTHSC IRB may request that the reviewing IRB re-evaluate its determination in light of any concerns identified by the UTHSC IRB in its administrative review of the submission;

v. If applicable, the UTHSC IRB determines that the results of any HHS or FDA audits of the reviewing IRB conducted within the last five years are satisfactory; and

vi. Brief review of the SOPs of the reviewing IRB determines that they satisfy all applicable federal regulatory requirements.

d. During this time, the site principal investigator will be advised to wait for confirmation that UTHSC is amenable to relying on the proposed reviewing IRB prior to registering the study in iMedRIS or submitting the study to the proposed reviewing IRB.

e. If the study does not meet the initial criteria for reliance on an external IRB, the site principal investigator will be advised to submit an iMedRIS application for local IRB review.

f. When vetting the reviewing IRB, the UTHSC IRB will assess the qualifications of the designated external IRB to serve as the reviewing IRB. The IRB Reliance Manager, in consultation with the IRB Director or their designee, will determine whether these criteria are satisfied. If the reviewing IRB does not meet UTHSC’s requisite qualifications, the site principal investigator will be advised to submit an iMedRIS application for local IRB review.

g. If UTHSC determines the designated external IRB possesses the requisite qualifications to serve as the reviewing IRB, the site principal investigator will be provided with documents delineating UTHSC’s local requirements, the UTHSC Local Context Information Sheet and UTHSC Boilerplate Consent Form Language document, and advised to incorporate all applicable local requirements into the lead study team’s initial submission for the reviewing IRB or the modification request for the addition of UTHSC as a site if the initial submission has already been approved by the reviewing IRB.
study, or the modification for the addition of UTHSC as a site, should not be submitted to the reviewing IRB until the study has been registered in iMedRIS and the UTHSC IRB has acknowledged, via an outcome letter in iMedRIS, that local requirements have been fully satisfied.

h. The site principal investigator must register the study with the UTHSC IRB via iMedRIS, and receive a final acknowledgement letter, before the study is initiated at this site. The iMedRIS application will collect basic study information and ask questions to assess for requisite local ancillary reviews and other procedures (e.g., IBC or IACUC review, execution of data use agreements or material transfer agreements, etc.). The application must include all required components as follows:

i. Documents that will be submitted to the reviewing IRB, such as the application, protocol, consent form(s), investigator’s brochure, package inserts, recruitment materials, data collection tools, etc., with UTHSC’s local requirements having been incorporated according to (V)(3)(g);

ii. If the main study has already received approval from the reviewing IRB, a copy of the most recent IRB approval letter(s) (i.e., initial and continuing) that contain the current approval and expiration dates for the overall study as well as the regulatory categories and/or level of review under which the main study was approved; and

iii. An unsigned copy of the proposed reliance agreement completed in accord with the IRB Agreement – Instructions for Use (NOTE: A copy of the reliance agreement does not need to be attached to the submission if the study will be conducted under an existing IRB authorization agreement that has been fully executed and is already on file with the UTHSC IRB, such as the overarching agreements maintained with St. Jude Children’s Research Hospital, the National Cancer Institute (NCI) Central IRB (CIRB), the National Marrow Donor Program (NMDP), etc.).

i. Upon receipt of the iMedRIS application, the UTHSC IRB will review the following elements of the submission:

i. The qualifications of the site principal investigator and site investigator(s), and the adequacy of the research support staff, to serve as a local site for a multicenter study;

ii. The application to assess for any differences in local procedures, requisite local ancillary reviews (e.g., IBC, IACUC, RSC), institutional approvals (e.g., Le Bonheur Children’s Hospital, Methodist Healthcare - Memphis Hospitals/UT Methodist Physicians, and Regional One Health, etc.), and/or consultation with Sponsored Programs or the equivalent office at an affiliate institution regarding a possible data use agreement or materials transfer agreement;

iii. Potential discrepancies between the initial consultation survey and the application that may impact UTHSC’s decision to rely on the proposed reviewing IRB;

iv. The documents submitted to ensure UTHSC’s local requirements have been properly incorporated; and

v. The terms set forth in the reliance agreement, which may warrant further review by the UTHSC Office of Sponsored Programs as described below in (V)(3)(l).

j. Once the iMedRIS application has been reviewed and the UTHSC IRB has determined that all local documentation requirements have been satisfied, an outcome letter will be
issued via iMedRIS to the site principal investigator, study contact(s), and institutional contacts as applicable. The outcome letter will grant **permission for the acknowledged study materials to be submitted to the reviewing IRB** and will also include an administrative recommendation to send the final, approved documents and fully executed reliance agreement to the UTHSC IRB via the PI Response form in iMedRIS as soon as they become available. At this time, the reliance agreement will be signed by the UTHSC Institutional Official and sent to the reviewing IRB for full execution unless further review by the UTHSC Office of Sponsored Programs is warranted as described in (V)(3)(i).

k. Upon receipt of the final, IRB-approved study documents and fully executed reliance agreement, the UTHSC IRB will review the documentation for accuracy.
   i. If the documentation is accurate and appropriate, a final acknowledgment letter will be sent to the site principal investigator.
   ii. If the documentation contains errors, such as the reviewing IRB’s modification of required boilerplate language, administrative recommendations will be issued for corrections and a final acknowledgment letter will be issued upon receipt of the IRB-approved, corrected study documentation.

l. If an institution of which the reviewing or a relying IRB is a component requests the inclusion of **specific liability and/or indemnification language** in the reliance agreement, then the UTHSC Office of Sponsored Programs must review and approve the language before the University will enter into a reliance agreement incorporating the proposed language.

m. The reviewing IRB will be responsible for developing **HIPAA authorization language** in consent forms, as well as for making determinations regarding waivers or alterations of authorization under the HIPAA Privacy Rule, unless otherwise specified in the reliance agreement. If the UTHSC IRB has site-specific language that is required as part of the HIPAA authorization in its consent forms, this language will be communicated to the reviewing IRB for inclusion in the site-specific consent forms. Similarly, concerns of the UTHSC IRB regarding HIPAA waivers or alterations will be communicated to and negotiated with the reviewing IRB. Although HIPAA determinations will be made by the reviewing IRB unless otherwise specified in the reliance agreement, UTHSC remains solely responsible for fulfilling its obligations under the HIPAA Privacy Rule.

n. The study may not be initiated at the local site(s) prior to UTHSC and local site **institutional approval** of the reliance agreement and acceptance of the research application by the UTHSC IRB and any engaged affiliate institution via a final acknowledgement letter sent from iMedRIS. Further, the UTHSC IRB does not permit local initiation of a study covered under the reliance agreement or the local enrollment of study participants until its conduct at the local site(s) has been reviewed and approved by the reviewing IRB, and until all other applicable requirements and approvals (e.g., Institutional Biosafety Committee, Radiation Safety Committee, etc.) for the study have been secured.

o. Reliance agreements will not take effect until signed on behalf of UTHSC by the Vice Chancellor for Research as the UTHSC institutional official’s signatory designee and fully executed by the reviewing institution.
p. When the UTHSC IRB will serve as a relying IRB for more than one study under the same applicable reliance agreement (such as when relying on the CIRB or participating in a research consortium), the vetting process described above will occur only at the time of the initial reliance agreement request when the same reviewing IRB will be used for subsequent studies, unless UTHSC specifies otherwise.

q. The UTHSC IRB retains the prerogative to conduct a non-regulatory, full board review of any study for which it may serve as the relying IRB under a reliance agreement, if a request is made for such review by an affiliate institution for which it serves as the IRB of record under the latter’s FWA.

r. The UTHSC IRB will comply with the determinations of the reviewing IRB regarding initial review, continuing review, review of revisions, reportable events, as well as DSMB and device reports for studies covered under the reliance agreement. Documentation of these determinations must be provided within 10 business days of the reviewing IRB’s determination by the site principal investigator to the UTHSC IRB via the Documents from Reviewing IRB submission form in iMedRIS.

s. The UTHSC IRB will instruct local researchers, and their research staff, that they must cooperate with the reviewing IRB in its execution of responsibilities for initial review, continuing review, review of revisions, reportable events, as well as DSMB and device reports for the studies covered by the reliance agreement, that they must adhere to the reviewing IRB’s policies and procedures, and that they must provide information requested by the reviewing IRB in a timely manner.

t. The UTHSC IRB will provide to the reviewing IRB or site principal investigator any requested information regarding local requirements and local research context issues prior to the reviewing IRB’s review of the conduct of the study at the local site(s).

u. For studies subject to HHS regulations for the protection of human subjects, the UTHSC IRB will be responsible for seeking required additional approvals from HHS when studies at the local site(s) involve pregnant women, fetuses and neonates, children, or prisoners, unless an alternative process has been delineated in the reliance agreement.

v. The UTHSC IRB requires that researchers obtain, document, and maintain records of consent, assent, and parental permission by each participant, LAR, and parent/legal guardian as specified by the reviewing IRB. The consent, assent, and parental permission documents must also include locally required consent template language as specified in the reliance agreement.

w. The UTHSC IRB requires that any proposed revisions in research must be submitted beforehand to the reviewing IRB and cannot be implemented without prior approval by the reviewing IRB, except where necessary to eliminate apparent immediate hazards to the participants.

x. The UTHSC IRB requires its researchers and research staff to disclose conflicts of interest (COIs) in accord with UTHSC and UTHSC IRB policies. The UTHSC IRB will convey to the reviewing IRB any management plan that results from the local COI review process. The reviewing IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation of the affected personnel in the research study and may propose additional requirements for the management plan in consultation with the UTHSC IRB. In the event that the reviewing
IRB considers additional elements appropriate for the management plan, the UTHSC IRB will negotiate the terms of a final plan. If UTHSC or the reviewing IRB is unable to accept the additional elements of the management plan as negotiated, then the research cannot be conducted at the local site(s). Management plans must be finalized and implemented before the study can be initiated or continued (if the conflict arises during conduct of the study) at the local site(s).

y. The UTHSC IRB will determine whether an organizational conflict of interest exists at the local study site. If so, the UTHSC IRB will submit a description of the organizational conflict of interest and proposed management plan to the reviewing IRB. The reviewing IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation of the relying site in the research study and may propose additional requirements for the management plan in consultation with UTHSC. If UTHSC or the reviewing IRB is unable to accept the additional elements of the management plan as negotiated, then the research cannot be conducted at the local site(s).

z. The UTHSC IRB requires that researchers promptly report to the reviewing IRB any local unanticipated problems involving risks to subjects or others according to the requirements specified in the reliance agreement. These unanticipated problems must also be reported to the UTHSC IRB no less than 10 business days after the reviewing IRB has made a determination via the Documents from Reviewing IRB form in iMedRIS.

aa. Local investigators must promptly provide to the UTHSC IRB all data and safety monitoring reports as well as device reports received from the overall principal investigator or the reviewing IRB no less than 10 business days after the reviewing IRB has made a determination via the Documents from Reviewing IRB form in iMedRIS.

bb. The UTHSC IRB will audit studies in cooperation with the reviewing IRB and according to any procedures specified in the reliance agreement. The results of those audits will be shared with the site principal investigator and the reviewing IRB by the UTHSC IRB.

c. The site principal investigator must promptly report to the reviewing IRB and the UTHSC IRB any potential instances of non-compliance, including results of audits, complaints, and protocol deviations. Such events initially identified by the UTHSC IRB will be promptly reported to the reviewing IRB by the UTHSC IRB.

dd. The UTHSC IRB will determine whether incidences of serious or continuing non-compliance require suspension or termination of such studies at the local site(s), unless an alternative process has been delineated in the reliance agreement.

e. For studies subject to HHS and/or FDA regulations for the protection of human subjects, the UTHSC IRB will determine whether any incident of non-compliance is serious or continuing and requires reporting to institutional officials and sponsors, including the federal government, unless an alternative process has been delineated in the reliance agreement.

ff. Researchers and research staff at the local site(s) must meet UTHSC IRB requirements for training in the ethics and regulation of human subjects research, unless otherwise specified in the reliance agreement.
gg. For NIH-funded studies, the UTHSC IRB will assure that local investigators meet the additional requirements of the NIH Genomic Data Sharing Policy, unless responsibility for this process is otherwise specified in the reliance agreement.

hh. The UTHSC IRB will promptly notify the reviewing IRB when local policies undergo major revisions that may affect the determinations assigned to the reviewing IRB under the reliance agreement, such as policies affecting reliance agreements or local context considerations.

ii. The UTHSC IRB will provide the site principal investigator and research staff with information regarding the local IRB Reliance Manager from whom they may obtain answers to questions, express concerns, and/or convey suggestions regarding the use of the reviewing IRB.

jj. In the event that the reliance agreement is terminated by either party, within 30 business days, the UTHSC IRB will assume responsibility of oversight for any study conducted at the local site(s) and previously covered by the reliance agreement, until such time as the relevant study is closed or a reliance agreement is established with another institution.

4. Responsibilities of Site Principal Investigators with UTHSC as the Relying IRB
   a. The site principal investigator and research team are responsible for understanding the requirements of the reliance agreement under which the local site is participating in the study.
   b. The site principal investigator must be knowledgeable about and follow the reviewing IRB’s policies and procedures as outlined in its SOPs and ensure that other site investigators and research staff are provided those policies and procedures.
   c. The site principal investigator may not initiate the study covered under the reliance agreement or enroll study participants until its conduct at the local site(s) has been approved by the reviewing IRB.
   d. The site principal investigator may not initiate the study at the local site(s) prior to UTHSC and local site institutional approval of the reliance agreement and acceptance of the research application by the UTHSC IRB via a final acknowledgement letter sent from iMedRIS.
   e. The UTHSC IRB does not permit local initiation of a study covered under the reliance agreement or the local enrollment of study participants until all other applicable requirements and approvals (e.g., Institutional Biosafety Committee, Radiation Safety Committee, full execution of applicable data use agreement(s) and/or material transfer agreement(s), etc.) for the study have been secured.
   f. The site principal investigator must comply with the determinations of the reviewing IRB with regard to initial review, continuing review, review of revisions, reportable events, as well as DSMB and device reports for studies covered under the reliance agreement. Documentation of these determinations must be provided within 10 business days of the reviewing IRB’s determination by the site principal investigator to the UTHSC IRB via the Documents from Reviewing IRB submission form in iMedRIS.
   g. The site principal investigator must provide information requested by the reviewing IRB (e.g., differences in local procedures and/or resources, reports pertaining to the
conduct of the research at the local site(s), investigator qualifications, etc.) in a timely manner.

h. The site principal investigator must obtain, document, and maintain records of consent, assent, and parental permission by each participant, LAR, and parent/guardian as specified by the reviewing IRB. The consent, assent, and parental permission documents must also include **locally required consent template language** as specified in the reliance agreement.

i. The site principal investigator is responsible for submitting any **proposed local revisions in the research** to the reviewing IRB, which cannot be implemented without prior approval by the reviewing IRB, except where necessary to eliminate apparent immediate hazards to the participants.

j. The site principal investigator is responsible for ensuring that all local researchers and research staff disclose **conflicts of interest** in accord with UTHSC and UTHSC IRB policies. The UTHSC IRB will convey to the reviewing IRB any management plan that results from the local COI review process. The reviewing IRB assumes final authority for determining whether the proposed management plan is sufficient to allow participation of the affected personnel in the research study and may propose additional requirements for the management plan in consultation with the UTHSC IRB. In the event that the reviewing IRB considers additional elements appropriate for the management plan, the UTHSC IRB will negotiate the terms of a final plan. If UTHSC or the reviewing IRB is unable to accept the additional elements of the management plan as negotiated, then the research cannot be conducted at the local site(s). Management plans must be finalized and implemented before the study can be initiated or continued (if the conflict arises during conduct of the study) at the local site(s).

k. The site principal investigator is responsible for promptly reporting to the reviewing IRB any **local unanticipated problems** involving risks to subjects or others according to the requirements specified in the reliance agreement. These unanticipated problems must also be reported to the UTHSC IRB after the reviewing IRB has made a determination.

l. The site principal investigator must promptly provide to the UTHSC IRB all **data and safety monitoring reports** as well as **device reports** received from the overall principal investigator or reviewing IRB no less than 10 business days after the reviewing IRB has made a determination.

m. The site principal investigator must cooperate with the reviewing IRB and the UTHSC IRB in the completion of any **audits** conducted according to procedures specified in the reliance agreement. The results of those audits will be shared with the site principal investigator by the UTHSC IRB.

n. The site principal investigator must promptly report to the reviewing IRB and the UTHSC IRB any potential instances at the local site(s) of **non-compliance**, including results of audits, complaints, and protocol deviations. Such events initially identified by the UTHSC IRB will be promptly reported to the reviewing IRB.

o. The site principal investigator is responsible for ensuring that local researchers and research staff meet UTHSC IRB requirements for **training** in the ethics and regulation of human subjects research, unless otherwise specified in the reliance agreement.
p. The site principal investigator is responsible for submitting all **changes to local key study personnel**, including the addition or removal of local personnel, replacement of the site principal investigator, as well as modification of study roles, via the **Documents from Reviewing IRB** form in iMedRIS prior to implementation of the changes. The UTHSC IRB will issue an acknowledgement letter from iMedRIS documenting acceptance of the changes, at which time the requested changes may be implemented.

5. Use of the SMART IRB Reliance Agreement
   a. When a UTHSC investigator proposes in the reliance agreement request to participate in a multicenter study being conducted by institutions that are members of the SMART IRB consortium, the UTHSC IRB will generally utilize the **SMART IRB reliance agreement** to operate in its role as either the reviewing IRB or a relying IRB.
   b. If the research is to be conducted at an **affiliate institution** that designates the UTHSC IRB as its IRB of record under its FWA (e.g., Le Bonheur Children’s Hospital, Methodist Healthcare - Memphis Hospitals/UT Methodist Physicians, or Regional One Health), the SMART IRB reliance agreement may only be used if that institution is also a member of the SMART IRB consortium.
   c. Although UTHSC will accept the use of the SMART IRB reliance agreement when participating in a multicenter study conducted by institutions that are members of the SMART IRB consortium, the decision of the UTHSC IRB to serve as the reviewing IRB or as a relying IRB under the SMART IRB reliance agreement is made on a case-by-case basis utilizing the **assessment criteria** outlined in sections (V)(1)(a and c) and (V)(3)(a-c) above for establishing reliance agreements.
   d. Any affiliate institution that designates the UTHSC IRB as its IRB of record under its FWA and is an institutional member of the SMART IRB consortium will determine on a case-by-case basis whether to allow studies on its premises for which the UTHSC IRB will serve as either the reviewing IRB or a relying IRB under the SMART IRB reliance agreement.
   e. The terms of the SMART IRB reliance agreement cannot be amended or altered. However, addenda may be added to address the flexible terms of the SMART IRB agreement and/or matters not explicitly addressed in the body of the agreement (such as issues related to liability and indemnification) at the request of UTHSC or any affiliate institution at which a study will be conducted.
   f. If policies and/or procedures required by a funder, network, or designated IRB are inconsistent with the terms of the SMART IRB reliance agreement, then the requirements of the funding source, network, or designated central IRB will apply and override the requirements of the SMART IRB reliance agreement.
   g. Other reliance agreements are permitted among SMART IRB institutions. If a UTHSC investigator proposes to participate in a multicenter study conducted among members of the SMART IRB consortium, but the agreement cannot be used locally (e.g., because the clinical site proposed is not a member of the SMART IRB consortium), then the UTHSC IRB will consider a separate reliance agreement with the reviewing IRB to enable participation of the local investigator(s) in the study.
h. The UTHSC IRB retains the prerogative to conduct a non-regulatory, full board review of any study for which it may serve as the relying IRB under the SMART IRB reliance agreement, if a request is made for such review by an affiliate institution for which it serves as the IRB of record under the latter’s FWA.